Mozart Therapeutics
Monica Anderson Childs is a seasoned scientist with extensive experience in biology and therapeutic research. Currently serving as Sr Scientist at Mozart Therapeutics, Inc since October 2022, Monica previously held the position of Sr Scientist in In Vitro Biology at Silverback Therapeutics from August 2017 to July 2022. Monica's earlier roles include Scientist at Revalesio, Associate Scientist at ZymoGenetics, and Research Associate at both ZymoGenetics and the University of Washington. Academic qualifications include a BS in Biochemistry from the University of Washington and a Certificate in Clinical Trials from the same institution.
Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.